SAN DIEGO, July 18, 2018 /PRNewswire/ -- Imprimis
Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused
pharmaceutical company, today announced that its Chief Executive
Officer, Mark L. Baum, will present
an update on the company's business at the Canaccord Genuity
38th Annual Growth Conference on Thursday, August 9th, 2018 at
11:00 a.m. ET in the London Room at
the InterContinental Boston Hotel in Boston, MA. The presentation will be
broadcast via a live webcast and an archive of the presentation
will be available for 365 days following the event. The
webcast can be accessed by clicking on the following link:
http://wsw.com/webcast/canaccord30/immy/. The Investor
Relations section of the Imprimis website will have a link to the
webcast as well, which can be found by clicking here. Mark
and Chief Financial Officer, Andrew
Boll, will be hosting one-on-one meetings at the conference
and attendees can contact their Canaccord representative to arrange
a meeting.
ABOUT IMPRIMIS PHARMACEUTICALS
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a rapidly
growing commercial-stage pharmaceutical company based in
San Diego, California. In
addition to owning the nation's leading ophthalmology
pharmaceutical compounding business, ImprimisRx, the Company holds
large equity positions in Eton Pharmaceuticals, Surface
Pharmaceuticals and Melt Pharmaceuticals, companies originally
founded as subsidiaries of Imprimis. The Company also owns
royalty rights in certain 505(b)(2) drug candidates being developed
by Eton, Surface and Melt. For more information about
Imprimis, please visit the Investor Relations section of the
corporate website by clicking here.
SAFE HARBOR
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward looking statements."
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is FDA-approved. Other
than drugs compounded at a registered outsourcing facility, all
Imprimis compounded formulations require a prescription for an
individually identified patient consistent with federal and state
laws.
CONTACTS
Investor Contact:
Jon
Patton
jpatton@imprimispharma.com
858-704-4587
View original content with
multimedia:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-on-august-9-2018-300682634.html
SOURCE Imprimis Pharmaceuticals, Inc.